Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study

被引：7
|
作者：
Mascarenhas, John
Higgins, Brian
Anders, Doreen
Burbury, Kate
El-Galaly, Tarec Christoffer
Gerds, Aaron T.
Gupta, Vikas
Kovic, Bruno
Maffioli, Margherita
Mesa, Ruben
Palmer, Jeanne M.
Passamonti, Francesco
Rambaldi, Alessandro
Ross, David M.
Vannucchi, Alessandro M.
Yacoub, Abdulraheem
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-135868
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Real-World Dosing Patterns of Ruxolitinib in Patients with Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea
    Altomare, Ivy
    Nguyen, Anna
    Parasuraman, Shreekant
    Paranagama, Dilan
    Kish, Jonathan K.
    Lord, Kevin
    Colucci, Philomena
    BLOOD, 2019, 134
  • [32] RUXOLITINIB PROVES SUPERIOR TO BEST AVAILABLE THERAPY IN A PROSPECTIVE, RANDOMIZED, PHASE 3 STUDY (RESPONSE) IN PATIENTS WITH POLYCYTHEMIA VERA RESISTANT TO OR INTOLERANT OF HYDROXYUREA
    Vannucchi, A. M.
    Kiladjian, J. J.
    Griesshammer, M.
    Masszi, T.
    Durrant, S.
    Passamonti, F.
    Harrison, C. N.
    Pane, F.
    Zachee, P.
    Mesa, R.
    He, S.
    Jones, M. M.
    Garrett, W.
    Li, J.
    Francillard, N.
    Habr, D.
    Verstovsek, S.
    HAEMATOLOGICA, 2014, 99 : 790 - 790
  • [33] RESPONSE 2: A phase 3b study evaluating the efficacy and safety of ruxolitinib in patients with bydroxyurea (HU)- resistant/intolerant polycytheinia vera (PV) versus best available therapy (BAT).
    Passamonti, Francesco
    Saydam, Guray
    Lim, Liberata
    Khan, Mahmudul H.
    Mounedji, Nadjat
    Griasshammer, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Treatment with ropeginterferon alfa-2b in patients with hydroxyurea resistant or intolerant polycythemia vera in South Korea: one-year results from a phase 2 study
    Yoon, Seug Yun
    Lee, Sung-Eun
    BLOOD RESEARCH, 2024, 59 (01)
  • [35] ACUTE-LEUKEMIA (AL), HYDROXYUREA (HU) AND POLYCYTHEMIA-VERA (PV) - AN ANALYSIS OF RISK FROM THE POLYCYTHEMIA-VERA STUDY-GROUP (PVSG)
    FRUCHTMAN, SM
    KAPLAN, ME
    PETERSON, P
    MACK, K
    BERK, PD
    WASSERMAN, LR
    BLOOD, 1994, 84 (10) : A518 - A518
  • [36] Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study
    Merx, Kirsten
    Fabarius, Alice
    Erben, Philipp
    Griesshammer, Martin
    Reiter, Andreas
    Hofmann, Wolf-Karsten
    Hehlmann, Ruediger
    Hochhaus, Andreas
    Lengfelder, Eva
    ANNALS OF HEMATOLOGY, 2013, 92 (07) : 907 - 915
  • [37] Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study
    Kirsten Merx
    Alice Fabarius
    Philipp Erben
    Martin Griesshammer
    Andreas Reiter
    Wolf-Karsten Hofmann
    Rüdiger Hehlmann
    Andreas Hochhaus
    Eva Lengfelder
    Annals of Hematology, 2013, 92 : 907 - 915
  • [38] AOP2014 shows promising efficacy and safety in a phase I/II study in patients with Polycythemia Vera
    Buxhofer-Ausch, V
    Greif, R.
    Thaler, J.
    Schloegl, E.
    Wolf, D.
    Kralovics, R.
    Gisslinger, B.
    Lechner, D.
    Strecker, K.
    Egele, A.
    Melchardt, T.
    Burgstaller, S.
    Gastl, G.
    Willenbacher, E.
    Zoerer, M.
    Zahriychuk, O.
    Klade, C.
    Gisslinger, H.
    ONKOLOGIE, 2013, 36 : 110 - 111
  • [39] The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study
    Mascarenhas, John
    Passamonti, Francesco
    Burbury, Kate
    El-Galaly, Tarec Christoffer
    Gerds, Aaron
    Gupta, Vikas
    Higgins, Brian
    Wonde, Kathrin
    Jamois, Candice
    Kovic, Bruno
    Huw, Ling-Yuh
    Katakam, Sudhakar
    Maffioli, Margherita
    Mesa, Ruben
    Palmer, Jeanne
    Bellini, Marta
    Ross, David M.
    Vannucchi, Alessandro M.
    Yacoub, Abdulraheem
    BLOOD ADVANCES, 2022, 6 (04) : 1162 - 1174
  • [40] Feasibility of recruitment of hydroxyurea-resistant or intolerant ET and PV patients into the MAJIC study
    Harrison, C. N.
    Mean, A.
    Fox, S.
    Bell, H.
    Aliman, S.
    Green, A.
    Wood, M.
    Ewing, J.
    Chen, F.
    Yap, C.
    Ahmed, I.
    Coppell, J.
    Knapper, S.
    McMullin, M. F.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 80 - 81
12345